Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Practice, Preferences, and Practical Tips From Primary Care Physicians to Improve the Care of Cancer Survivors.

McDonough AL, Rabin J, Horick N, Lei Y, Chinn G, Campbell EG, Park ER, Peppercorn J.

J Oncol Pract. 2019 May 31:JOP1800740. doi: 10.1200/JOP.18.00740. [Epub ahead of print]

PMID:
31150311
2.

The Impact of Chest Wall Boost on Reconstruction Complications and Local Control in Patients Treated for Breast Cancer.

Naoum GE, Salama L, Ho A, Horick NK, Oladeru O, Abouegylah M, Daniell K, MacDonald S, Arafat WO, Smith BL, Colwell AS, Taghian AG.

Int J Radiat Oncol Biol Phys. 2019 May 2. pii: S0360-3016(19)30659-5. doi: 10.1016/j.ijrobp.2019.04.027. [Epub ahead of print]

PMID:
31055108
3.

Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer.

Yerramilli D, Drapek L, Nipp RD, Horick N, Moran SMC, Noé B, D'Arpino SM, Mitra D, Hong TS, Ryan DP, Dizon DS, Wo J.

J Gastrointest Cancer. 2019 Apr 13. doi: 10.1007/s12029-019-00233-w. [Epub ahead of print]

PMID:
30980294
4.

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.

El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA.

Leukemia. 2019 Mar 28. doi: 10.1038/s41375-019-0449-1. [Epub ahead of print]

PMID:
30923318
5.

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.

Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32029. [Epub ahead of print]

PMID:
30913304
6.

Are rare cancer survivors at elevated risk of subsequent new cancers?

Finkelstein DM, Horick NK, Ramchandani R, Boyd KL, Rana HQ, Bychkovsky BL.

BMC Cancer. 2019 Feb 21;19(1):166. doi: 10.1186/s12885-019-5358-1.

7.

High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.

Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY.

Oncologist. 2019 Jun;24(6):e275-e283. doi: 10.1634/theoncologist.2018-0794. Epub 2019 Feb 12.

PMID:
30755500
8.

Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.

Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC.

Breast Cancer Res Treat. 2019 Jan;173(2):375-383. doi: 10.1007/s10549-018-5013-6. Epub 2018 Oct 22.

PMID:
30350269
9.

Physical symptoms in long-term survivors of rare cancer.

Horick NK, Muzikansky A, Gutierrez HL, Boyd KL, Finkelstein DM.

J Cancer Surviv. 2018 Dec;12(6):835-842. doi: 10.1007/s11764-018-0721-9. Epub 2018 Oct 12.

PMID:
30315392
10.

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00037. Epub 2018 Jul 23.

11.

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, Shaw AT, Mehan WA, Shih HA, Gainor JF.

J Thorac Oncol. 2018 Apr;13(4):550-558. doi: 10.1016/j.jtho.2018.01.012. Epub 2018 Jan 31.

12.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

13.

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529.

Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY.

Adv Radiat Oncol. 2017 Feb 6;2(2):110-117. doi: 10.1016/j.adro.2017.01.009. eCollection 2017 Apr-Jun.

14.

Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.

Peppercorn J, Horick N, Houck K, Rabin J, Villagra V, Lyman GH, Wheeler SB.

Cancer. 2017 Jul 1;123(13):2506-2515. doi: 10.1002/cncr.30629. Epub 2017 Feb 14.

15.

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH.

Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.

16.

Physical and psychological health in rare cancer survivors.

Horick NK, Manful A, Lowery J, Domchek S, Moorman P, Griffin C, Visvanathan K, Isaacs C, Kinney AY, Finkelstein DM.

J Cancer Surviv. 2017 Feb;11(1):158-165. doi: 10.1007/s11764-016-0573-0. Epub 2016 Oct 19.

17.

Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ.

Cancer. 2016 Nov 15;122(21):3297-3306. doi: 10.1002/cncr.30196. Epub 2016 Jul 15.

18.

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.

Buchanan AH, Voils CI, Schildkraut JM, Fine C, Horick NK, Marcom PK, Wiggins K, Skinner CS.

J Genet Couns. 2017 Feb;26(1):79-92. doi: 10.1007/s10897-016-9981-6. Epub 2016 Jun 6.

19.

Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project.

Patel SG, Ahnen DJ, Kinney AY, Horick N, Finkelstein DM, Hill DA, Lindor NM, MaCrae F, Lowery JT.

Am J Gastroenterol. 2016 Feb;111(2):285-93. doi: 10.1038/ajg.2015.397. Epub 2016 Feb 9.

20.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
21.

Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer.

Ferguson CM, Swaroop MN, Horick N, Skolny MN, Miller CL, Jammallo LS, Brunelle C, O'Toole JA, Salama L, Specht MC, Taghian AG.

J Clin Oncol. 2016 Mar 1;34(7):691-8. doi: 10.1200/JCO.2015.61.5948. Epub 2015 Dec 7.

22.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW.

JAMA Oncol. 2015 Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690.

PMID:
26270727
23.

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.

O'Donnell E, Mahindra A, Yee AJ, Nardi V, Birrer N, Horick N, Borger D, Finkelstein D, Iafrate JA, Raje N.

EBioMedicine. 2014 Nov 18;2(1):71-3. doi: 10.1016/j.ebiom.2014.11.008. eCollection 2015 Jan.

24.

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.

Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O'Toole JA, Isakoff SJ, Specht MC, Taghian AG.

Breast Cancer Res Treat. 2015 Jun;151(2):393-403. doi: 10.1007/s10549-015-3408-1. Epub 2015 May 5.

25.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17:56. doi: 10.1186/s13058-015-0568-1.

26.

Radiation therapy risk factors for development of lymphedema in patients treated with regional lymph node irradiation for breast cancer.

Chandra RA, Miller CL, Skolny MN, Warren LE, Horick N, Jammallo LS, Sadek BT, Shenouda MN, O'Toole J, Specht MC, Taghian AG.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):760-4. doi: 10.1016/j.ijrobp.2014.12.029.

PMID:
25752389
27.

The impact of breast cancer-related lymphedema on the ability to perform upper extremity activities of daily living.

O'Toole JA, Ferguson CM, Swaroop MN, Horick N, Skolny MN, Brunelle CL, Miller CL, Jammallo LS, Specht MC, Taghian AG.

Breast Cancer Res Treat. 2015 Apr;150(2):381-8. doi: 10.1007/s10549-015-3325-3. Epub 2015 Mar 7.

PMID:
25749734
28.

Immediate Implant Reconstruction Is Associated With a Reduced Risk of Lymphedema Compared to Mastectomy Alone: A Prospective Cohort Study.

Miller CL, Colwell AS, Horick N, Skolny MN, Jammallo LS, O'Toole JA, Shenouda MN, Sadek BT, Swaroop MN, Ferguson CM, Smith BL, Specht MC, Taghian AG.

Ann Surg. 2016 Feb;263(2):399-405. doi: 10.1097/SLA.0000000000001128.

29.

Factors associated with fear of lymphedema after treatment for breast cancer.

Jammallo LS, Miller CL, Horick NK, Skolny MN, O'Toole J, Specht MC, Taghian AG.

Oncol Nurs Forum. 2014 Sep;41(5):473-83. doi: 10.1188/14.ONF.473-483.

PMID:
25158653
30.

Long-term risk of medical conditions associated with breast cancer treatment.

Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM.

Breast Cancer Res Treat. 2014 May;145(1):233-43. doi: 10.1007/s10549-014-2928-4. Epub 2014 Apr 3.

31.

A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network.

Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, Sandler RS, Burke C, Hill DA, Ahnen DJ.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):601-10. doi: 10.1158/1055-9965.EPI-13-1085. Epub 2014 Feb 5.

32.

Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients.

Miller CL, Specht MC, Skolny MN, Horick N, Jammallo LS, O'Toole J, Shenouda MN, Sadek BT, Smith BL, Taghian AG.

Breast Cancer Res Treat. 2014 Feb;144(1):71-7. doi: 10.1007/s10549-014-2856-3. Epub 2014 Feb 6.

33.

The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study.

Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, Shenouda MN, O'Toole JA, MacDonald SM, Specht MC, Taghian AG.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):565-71. doi: 10.1016/j.ijrobp.2013.11.232. Epub 2014 Jan 7.

34.

Prognostic significance of indeterminate lung nodules in renal cell carcinoma.

Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD.

Urol Oncol. 2014 Apr;32(3):355-61. doi: 10.1016/j.urolonc.2013.09.001. Epub 2014 Jan 4.

PMID:
24397994
35.

A novel, validated method to quantify breast cancer-related lymphedema (BCRL) following bilateral breast surgery.

Miller CL, Specht MC, Horick N, Skolny MN, Jammallo LS, O'Toole J, Taghian AG.

Lymphology. 2013 Jun;46(2):64-74.

PMID:
24354105
36.

Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer.

Jammallo LS, Miller CL, Singer M, Horick NK, Skolny MN, Specht MC, O'Toole J, Taghian AG.

Breast Cancer Res Treat. 2013 Nov;142(1):59-67.

37.

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.

Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr.

Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183. Epub 2013 Aug 26.

38.

Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Specht MC, Miller CL, Russell TA, Horick N, Skolny MN, O'Toole JA, Jammallo LS, Niemierko A, Sadek BT, Shenouda MN, Finkelstein DM, Smith BL, Taghian AG.

Breast Cancer Res Treat. 2013 Aug;140(3):485-94. doi: 10.1007/s10549-013-2655-2. Epub 2013 Aug 4.

39.

Cording following treatment for breast cancer.

O'Toole J, Miller CL, Specht MC, Skolny MN, Jammallo LS, Horick N, Elliott K, Niemierko A, Taghian AG.

Breast Cancer Res Treat. 2013 Jul;140(1):105-11. doi: 10.1007/s10549-013-2616-9. Epub 2013 Jun 29.

40.

Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients.

Specht MC, Miller CL, Skolny MN, Jammallo LS, O'Toole J, Horick N, Isakoff SJ, Smith BL, Taghian AG.

Ann Surg Oncol. 2013 Sep;20(9):2835-41. doi: 10.1245/s10434-012-2828-y. Epub 2013 May 21.

PMID:
23689935
41.

Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.

Le LP, Dias-Santagata D, Pawlak AC, Cosper AK, Nguyen AT, Selim MA, Deng A, Horick NK, Iafrate AJ, Mihm MC Jr, Hoang MP.

PLoS One. 2012;7(10):e47290. doi: 10.1371/journal.pone.0047290. Epub 2012 Oct 9.

42.

Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery.

Miller CL, Specht MC, Skolny MN, Jammallo LS, Horick N, O'Toole J, Coopey SB, Hughes K, Gadd M, Smith BL, Taghian AG.

Breast Cancer Res Treat. 2012 Oct;135(3):781-9. doi: 10.1007/s10549-012-2231-1. Epub 2012 Sep 1.

43.

The Family Health Promotion Project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families.

Lowery JT, Marcus A, Kinney A, Bowen D, Finkelstein DM, Horick N, Garrett K, Haile R, Sandler R, Ahnen DJ.

Contemp Clin Trials. 2012 Mar;33(2):426-35. doi: 10.1016/j.cct.2011.11.005. Epub 2011 Nov 12.

44.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

45.

Clinically relevant changes in family history of cancer over time.

Ziogas A, Horick NK, Kinney AY, Lowery JT, Domchek SM, Isaacs C, Griffin CA, Moorman PG, Edwards KL, Hill DA, Berg JS, Tomlinson GE, Anton-Culver H, Strong LC, Kasten CH, Finkelstein DM, Plon SE.

JAMA. 2011 Jul 13;306(2):172-8. doi: 10.1001/jama.2011.955.

46.

Predictors of feeding gastrostomy tube removal in stroke patients with dysphagia.

Ickenstein GW, Kelly PJ, Furie KL, Ambrosi D, Rallis N, Goldstein R, Horick N, Stein J.

J Stroke Cerebrovasc Dis. 2003 Jul-Aug;12(4):169-74.

PMID:
17903923
47.

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.

Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW.

Chest. 2007 Oct;132(4):1239-46. Epub 2007 Jul 23.

PMID:
17646232
48.

Peptide-mediated selective adhesion of smooth muscle and endothelial cells in microfluidic shear flow.

Plouffe BD, Njoka DN, Harris J, Liao J, Horick NK, Radisic M, Murthy SK.

Langmuir. 2007 Apr 24;23(9):5050-5. Epub 2007 Mar 21.

PMID:
17373836
49.

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW.

Thorax. 2007 Jul;62(7):569-76. Epub 2007 Mar 13.

50.

Pooling of case specimens to create standard serum sets for screening cancer biomarkers.

Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41.

Supplemental Content

Loading ...
Support Center